ClearBridge Adds Axsome as Biotech Bet Lags AI Rally

ClearBridge Investments initiated a position in Axsome Therapeutics during the second quarter, betting on the expanding market for its central nervous system drug, Auvelity. The biopharmaceutical company closed at $241.53 on July 23, giving it a market capitalization of $12.43 billion.

The fund manager highlighted the drug's recent regulatory expansion as a primary catalyst for the investment. "We believe that its key drug, Auvelity, has a large commercial opportunity with approval in Major Depressive Disorder and recent expansion into Alzheimer's Disease Agitation," ClearBridge stated in its second-quarter investor letter.

This new allocation underscores a growing divide within the small-cap growth sector. The Russell 2000 Growth Index surged 25.6% over the quarter, marking its third-best quarterly performance in two decades. However, that rally was heavily concentrated in a narrow band of themes.

Gains were largely fueled by speculative enthusiasm for generative AI infrastructure, strength in biotech, and a surge in high-beta, high-momentum stocks. Rising retail trading activity further amplified these specific market leaders, creating a challenging environment for fundamentally driven stock pickers.

ClearBridge's Small Cap Growth Strategy returned more than 21% on a gross basis during the period. While a strong absolute return, it lagged the broader benchmark. The shortfall was attributed to limited exposure to the high-momentum AI trades driving the index.

The fund also faced headwinds from underperformance in specific healthcare and financial holdings, as well as broader challenges within its software investments. Adding a high-growth, commercial-stage biotechnology name like Axsome appears to be a tactical response to this dynamic.

Axsome has been a notable market outlier. Its shares have gained 139.54% over the past 52 weeks, though the stock was essentially flat